Datasheet for ABIN5668253

Recombinant anti-IL-6R (Tocilizumab Biosimilar) antibody

1 Publication

Go to Product page

Overview

Quantity:	200 µg
Target:	IL-6R (Tocilizumab Biosimilar)
Reactivity:	Human
Host:	Human
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Conjugate:	This IL-6R (Tocilizumab Biosimilar) antibody is un-conjugated
Application:	ELISA, Inhibition Assay (InhA)

Product Details

Immunogen:	This antibody was prepared by CDR grafting of mouse AUK 12-20 antibody onto a human framework regions.
Clone:	RhPM-1
Isotype:	IgG1 kappa
Specificity:	Tocilizumab binds specifically to both the membrane bound and soluble forms of human IL-6R. The IL6 receptor is a protein complex consisting of an IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response.
Characteristics:	OriginalSpeciesName: Human OriginalFormat: IgG1

Product Details

Purification:	Purified antibody.
Purity:	> 98 % as determined by SDS-PAGE
Endotoxin Level:	Endotoxin is < 1.0 EU/mg as determined by the LAL method

Target Details

Target:	IL-6R (Tocilizumab Biosimilar)
Abstract:	IL-6R (Tocilizumab Biosimilar) Products
Target Type:	Biosimilar
Background:	IL6R, MRA, atlizumab
UniProt:	A0N0L5

Application Details

Application Notes:	Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines (to the same extent as the original AUK12-20 mouse antibody) - inhibits sIL-6R and mIL-6R-mediated signaling.
Comment:	NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.
Restrictions:	For Research Use only

Handling

Buffer:	PBS with 0.02 % Proclin 300.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	4 °C,-20 °C
Storage Comment:	Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Publications

Product cited in:	Hsieh, Hsu, Chang, Lai: "IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells." in: **Nature communications**, Vol. 9, Issue 1, pp. 463, (2018) (PubMed).